BN Business News
添加企业 →
本文翻译正在准备中。在此之前,我们暂时显示英文原文。

市场监管 · 1997/4/71 分钟阅读

2943174 Canada Inc., Also d/b/a United Research Center, Inc.; Analysis To Aid Public Comment

本地自动翻译 · 来源原始语言

摘要

In settlement of alleged violations of federal law prohibiting unfair or deceptive acts or practices and unfair methods of competition, this consent agreement, accepted subject to final Commission approval, would prohibit, among other things, the Quebec- based company and its president from making health benefits, performance, or efficacy claims regarding the ``Svelt-PATCH'' or any other drug or device unless, at the time the representation is made, the respondents possess and rely upon competent and reliable scientific evidence that substantiates the representation, and from misrepresenting the existence, contents, validity, results, conclusions, or interpretations of any test or study. In addition, the proposed consent agreement would require the respondents to pay $375,000 in consumer redress or disgorgement.

来源原始语言: Federal Register — Federal Trade Commission打开原始公告 →

探索专题

商业洞察 →